Insider Trading Activity Acorda Therapeutics, Inc. (NASDAQ:ACOR) – Director Sold 10,000 shares of Stock

ME Staff

7 years ago

Insider Trading Activity For Acorda Therapeutics, Inc. (NASDAQ:ACOR)

Barry E Greene , Director of Acorda Therapeutics, Inc. (NASDAQ:ACOR) reportedly Sold 10,000 shares of the company’s stock at an average price of 21.57 for a total transaction amount of $215,700.00 SEC Form

Insider Trading History For Acorda Therapeutics, Inc. (NASDAQ:ACOR)

On 11/13/2012 Sandra Phd Panem, Director, sold 22,569 with an average share price of $24.12 per share and the total transaction amounting to $544,364.28.View SEC Filing

On 12/3/2012 Ron Cohen, CEO, sold 16,407 with an average share price of $24.22 per share and the total transaction amounting to $397,377.54.View SEC Filing

On 12/3/2012 David Lawrence, CFO, sold 9,313 with an average share price of $24.21 per share and the total transaction amounting to $225,467.73.View SEC Filing

On 12/3/2012 Andrew Blight, Insider, sold 7,200 with an average share price of $24.20 per share and the total transaction amounting to $174,240.00.View SEC Filing

On 12/4/2012 Lauren M Sabella, VP, sold 4,364 with an average share price of $24.58 per share and the total transaction amounting to $107,267.12.View SEC Filing

On 5/8/2013 Sandra Phd Panem, Director, sold 10,000 with an average share price of $33.80 per share and the total transaction amounting to $338,000.00.View SEC Filing

On 6/10/2013 Ron Cohen, CEO, sold 11,000 with an average share price of $34.15 per share and the total transaction amounting to $375,650.00.View SEC Filing

Analyst Ratings For Acorda Therapeutics, Inc. (NASDAQ:ACOR)
These are 6 Hold Ratings, 3 Buy Ratings .
The current consensus rating for Acorda Therapeutics, Inc. (NASDAQ:ACOR) is Hold (Score: 2.33) with a consensus target price of $24.67 , a potential (13.41% upside)

Analyst Ratings History For Acorda Therapeutics, Inc. (NASDAQ:ACOR)

On 8/31/2015 Raymond James Financial, Inc. Initiated Coverage of rating Market Perform
On 6/1/2016 Aegis Boost Price Target of rating Buy with a price target of $40.00 to $52.00
On 11/23/2016 Leerink Swann Reiterated Rating Market Perform
On 1/8/2017 Evercore ISI Set Price Target of rating Hold with a price target of $23.00
On 2/15/2017 Cantor Fitzgerald Reiterated Rating Neutral to Positive
On 4/3/2017 Janney Montgomery Scott Downgraded rating Buy to Neutral with a price target of $38.00 to $19.00
On 4/3/2017 Goldman Sachs Group, Inc. (The) Reiterated Rating Neutral with a price target of $22.00

Recent Trading Activity for Acorda Therapeutics, Inc. (NASDAQ:ACOR)
Shares of Acorda Therapeutics, Inc. closed the previous trading session at 21.75 down -0.50 -2.25% with 791,709 shares trading hands.